Table 1. Open in new tab Demographic and...

	Baseline Seizure	Incident Seizure	No Seizure
N	127 (15%)	104 (13%)	590 (72%)
Cohort				.13
2010–2012 COAT	30 (14%)	21 (10%)	163 (76%)
2013–2014 ASTRO Pilot	16 (11%)	22 (15%)	111 (74%)
2015–2017 ASTRO-CM	81 (18%)	61 (13%)	316 (69%)
Demographics
Age, years	34 [29–40]	36 [29–42]	35 [30–40]	.92
Women	55 (43%)	46 (44%)	233 (39%)	.53
Glasgow Coma Score <15	78 (61%)	37 (36%)	209 (36%)	<.001
ART status				.65
ART naive	88 (69%)	63 (61%)	383 (65%)
On ART <4 months	11 (9%)	11 (11%)	59 (10%)
On ART >4 months	27 (21%)	29 (28%)	147 (25%)
Unknown ART status	1 (1%)	1 (1%)	1 (0%)
Symptom duration, days	21 [10–30]	14 [12–30]	14 [10–30]	.84
Blood Results
Absolute CD4 cells/μL	14 [6–35]	17 [6–58]	17 [7–55]	.07
CD4 <50 cells/μL	102 (84%)	73 (74%)	397 (72%)	.02
Sodium, mEq/L	128 [124–133]	129 [126–133]	130 [126–134]	.19
Glucose, mg/dL	110 [94–119]	104 [86–110]	100 [85–115]	.29
CSF Results
White cells/μL	<5 [<5–45]	<5 [<5–45]	<5 [<5–56]	.76
White cells <5 cells/μL	71 (58%)	59 (60%)	323 (57%)	.88
Protein, mg/dL	73 [36–120]	62 [27–124]	60 [24–125]	.28
Opening pressure, cm H₂O	33 [21–47]	27 [19–45]	26 [17–37]	.002
Opening pressure >25 cm H₂O	77 (68%)	49 (54%)	261 (51%)	.004
Cryptococcus CFU/mL CSF	125000 [12400–567000]	92000 [6883–360000]	36000 [1011–230 000]	<.001

Baseline Seizure

Incident Seizure

No Seizure

Median [IQR] or N (%)^a

P Value^b

127 (15%)

104 (13%)

590 (72%)

Cohort

.13

2010–2012 COAT

30 (14%)

21 (10%)

163 (76%)

2013–2014 ASTRO Pilot

16 (11%)

22 (15%)

111 (74%)

2015–2017 ASTRO-CM

81 (18%)

61 (13%)

316 (69%)

Demographics

Age, years

34 [29–40]

36 [29–42]

35 [30–40]

.92

Women

55 (43%)

46 (44%)

233 (39%)

.53

Glasgow Coma Score <15

78 (61%)

37 (36%)

209 (36%)

<.001

ART status

.65

ART naive

88 (69%)

63 (61%)

383 (65%)

On ART <4 months

11 (9%)

11 (11%)

59 (10%)

On ART >4 months

27 (21%)

29 (28%)

147 (25%)

Unknown ART status

1 (1%)

1 (0%)

Symptom duration, days

21 [10–30]

14 [12–30]

14 [10–30]

.84

Blood Results

Absolute CD4 cells/μL

14 [6–35]

17 [6–58]

17 [7–55]

.07

CD4 <50 cells/μL

102 (84%)

73 (74%)

397 (72%)

.02

Sodium, mEq/L

128 [124–133]

129 [126–133]

130 [126–134]

.19

Glucose, mg/dL

110 [94–119]

104 [86–110]

100 [85–115]

.29

CSF Results

White cells/μL

<5 [<5–45]

<5 [<5–56]

.76

White cells <5 cells/μL

71 (58%)

59 (60%)

323 (57%)

.88

Protein, mg/dL

73 [36–120]

62 [27–124]

60 [24–125]

.28

Opening pressure, cm H₂O

33 [21–47]

27 [19–45]

26 [17–37]

.002

Opening pressure >25 cm H₂O

77 (68%)

49 (54%)

261 (51%)

.004

Cryptococcus CFU/mL CSF

125000 [12400–567000]

92000 [6883–360000]

36000 [1011–230 000]

<.001

	Baseline Seizure	Incident Seizure	No Seizure
N	127 (15%)	104 (13%)	590 (72%)
Cohort				.13
2010–2012 COAT	30 (14%)	21 (10%)	163 (76%)
2013–2014 ASTRO Pilot	16 (11%)	22 (15%)	111 (74%)
2015–2017 ASTRO-CM	81 (18%)	61 (13%)	316 (69%)
Demographics
Age, years	34 [29–40]	36 [29–42]	35 [30–40]	.92
Women	55 (43%)	46 (44%)	233 (39%)	.53
Glasgow Coma Score <15	78 (61%)	37 (36%)	209 (36%)	<.001
ART status				.65
ART naive	88 (69%)	63 (61%)	383 (65%)
On ART <4 months	11 (9%)	11 (11%)	59 (10%)
On ART >4 months	27 (21%)	29 (28%)	147 (25%)
Unknown ART status	1 (1%)	1 (1%)	1 (0%)
Symptom duration, days	21 [10–30]	14 [12–30]	14 [10–30]	.84
Blood Results
Absolute CD4 cells/μL	14 [6–35]	17 [6–58]	17 [7–55]	.07
CD4 <50 cells/μL	102 (84%)	73 (74%)	397 (72%)	.02
Sodium, mEq/L	128 [124–133]	129 [126–133]	130 [126–134]	.19
Glucose, mg/dL	110 [94–119]	104 [86–110]	100 [85–115]	.29
CSF Results
White cells/μL	<5 [<5–45]	<5 [<5–45]	<5 [<5–56]	.76
White cells <5 cells/μL	71 (58%)	59 (60%)	323 (57%)	.88
Protein, mg/dL	73 [36–120]	62 [27–124]	60 [24–125]	.28
Opening pressure, cm H₂O	33 [21–47]	27 [19–45]	26 [17–37]	.002
Opening pressure >25 cm H₂O	77 (68%)	49 (54%)	261 (51%)	.004
Cryptococcus CFU/mL CSF	125000 [12400–567000]	92000 [6883–360000]	36000 [1011–230 000]	<.001

Table 1.

Open in new tab

Demographic and Clinical Parameters by Baseline Seizure

	Baseline Seizure	Incident Seizure	No Seizure
	Median [IQR] or N (%)^a	Median [IQR] or N (%)^a	Median [IQR] or N (%)^a	P Value^b
N	127 (15%)	104 (13%)	590 (72%)
Cohort				.13
2010–2012 COAT	30 (14%)	21 (10%)	163 (76%)
2013–2014 ASTRO Pilot	16 (11%)	22 (15%)	111 (74%)
2015–2017 ASTRO-CM	81 (18%)	61 (13%)	316 (69%)
Demographics
Age, years	34 [29–40]	36 [29–42]	35 [30–40]	.92
Women	55 (43%)	46 (44%)	233 (39%)	.53
Glasgow Coma Score <15	78 (61%)	37 (36%)	209 (36%)	<.001
ART status				.65
ART naive	88 (69%)	63 (61%)	383 (65%)
On ART <4 months	11 (9%)	11 (11%)	59 (10%)
On ART >4 months	27 (21%)	29 (28%)	147 (25%)
Unknown ART status	1 (1%)	1 (1%)	1 (0%)
Symptom duration, days	21 [10–30]	14 [12–30]	14 [10–30]	.84
Blood Results
Absolute CD4 cells/μL	14 [6–35]	17 [6–58]	17 [7–55]	.07
CD4 <50 cells/μL	102 (84%)	73 (74%)	397 (72%)	.02
Sodium, mEq/L	128 [124–133]	129 [126–133]	130 [126–134]	.19
Glucose, mg/dL	110 [94–119]	104 [86–110]	100 [85–115]	.29
CSF Results
White cells/μL	<5 [<5–45]	<5 [<5–45]	<5 [<5–56]	.76
White cells <5 cells/μL	71 (58%)	59 (60%)	323 (57%)	.88
Protein, mg/dL	73 [36–120]	62 [27–124]	60 [24–125]	.28
Opening pressure, cm H₂O	33 [21–47]	27 [19–45]	26 [17–37]	.002
Opening pressure >25 cm H₂O	77 (68%)	49 (54%)	261 (51%)	.004
Cryptococcus CFU/mL CSF	125000 [12400–567000]	92000 [6883–360000]	36000 [1011–230 000]	<.001

	Baseline Seizure	Incident Seizure	No Seizure
	Median [IQR] or N (%)^a	Median [IQR] or N (%)^a	Median [IQR] or N (%)^a	P Value^b
N	127 (15%)	104 (13%)	590 (72%)
Cohort				.13
2010–2012 COAT	30 (14%)	21 (10%)	163 (76%)
2013–2014 ASTRO Pilot	16 (11%)	22 (15%)	111 (74%)
2015–2017 ASTRO-CM	81 (18%)	61 (13%)	316 (69%)
Demographics
Age, years	34 [29–40]	36 [29–42]	35 [30–40]	.92
Women	55 (43%)	46 (44%)	233 (39%)	.53
Glasgow Coma Score <15	78 (61%)	37 (36%)	209 (36%)	<.001
ART status				.65
ART naive	88 (69%)	63 (61%)	383 (65%)
On ART <4 months	11 (9%)	11 (11%)	59 (10%)
On ART >4 months	27 (21%)	29 (28%)	147 (25%)
Unknown ART status	1 (1%)	1 (1%)	1 (0%)
Symptom duration, days	21 [10–30]	14 [12–30]	14 [10–30]	.84
Blood Results
Absolute CD4 cells/μL	14 [6–35]	17 [6–58]	17 [7–55]	.07
CD4 <50 cells/μL	102 (84%)	73 (74%)	397 (72%)	.02
Sodium, mEq/L	128 [124–133]	129 [126–133]	130 [126–134]	.19
Glucose, mg/dL	110 [94–119]	104 [86–110]	100 [85–115]	.29
CSF Results
White cells/μL	<5 [<5–45]	<5 [<5–45]	<5 [<5–56]	.76
White cells <5 cells/μL	71 (58%)	59 (60%)	323 (57%)	.88
Protein, mg/dL	73 [36–120]	62 [27–124]	60 [24–125]	.28
Opening pressure, cm H₂O	33 [21–47]	27 [19–45]	26 [17–37]	.002
Opening pressure >25 cm H₂O	77 (68%)	49 (54%)	261 (51%)	.004
Cryptococcus CFU/mL CSF	125000 [12400–567000]	92000 [6883–360000]	36000 [1011–230 000]	<.001

Abbreviations: ART, antiretroviral therapy; CFU, colony-forming units; COAT, Cryptococcal Optimal ART Timing; CSF, cerebrospinal fluid; IQR, interquartile range.

^aPercentages of each seizure group are displayed for categorical variables.

^bP values from Kruskal-Wallis tests for continuous variables and χ ² tests for categorical variables.

This Feature Is Available To Subscribers Only